168 related articles for article (PubMed ID: 20857708)
21. [CoLaus: diabetes and dyslipidemia, there is always something new!].
Vollenweider P; Vaucher J; Bastardot F; Schmid R; Vidal PM; Waeber G
Rev Med Suisse; 2011 Nov; 7(315):2122, 2124-6. PubMed ID: 22187780
[TBL] [Abstract][Full Text] [Related]
22. A novel component of the metabolic syndrome: the oxidative stress.
Hopps E; Noto D; Caimi G; Averna MR
Nutr Metab Cardiovasc Dis; 2010 Jan; 20(1):72-7. PubMed ID: 19747805
[TBL] [Abstract][Full Text] [Related]
23. [Guidelines for the management of atherosclerotic diseases in diabetes mellitus].
Kotake H; Oikawa S
Nihon Rinsho; 2006 Nov; 64(11):2074-80. PubMed ID: 17087299
[TBL] [Abstract][Full Text] [Related]
24. Diabetes and vascular disease.
Deedwania P; Srikanth S
Expert Rev Cardiovasc Ther; 2008 Jan; 6(1):127-38. PubMed ID: 18095912
[TBL] [Abstract][Full Text] [Related]
25. New insights into understanding cardiometabolic risk. Introduction.
Fonarow GC; Watson KE
Rev Cardiovasc Med; 2007; 8 Suppl 4():S1-2. PubMed ID: 17934389
[No Abstract] [Full Text] [Related]
26. Contrasting cardiovascular risk profiles and prescribed cardio-protective therapies in newly-diagnosed type 2 diabetes identified through screening and standard practice.
Webb DR; Gray LJ; Khunti K; Campbell S; Dallosso H; Davies MJ
Diabetes Res Clin Pract; 2011 Mar; 91(3):280-5. PubMed ID: 21194777
[TBL] [Abstract][Full Text] [Related]
27. Meeting of the minds. Should pre-hypertension in type 2 diabetes be treated?
Bihl G; Amod A; Ellis G; Moore R; Raal FJ; Gernholtz T; Schamroth C; Horak A
Cardiovasc J Afr; 2010; 21(3 Suppl):S9-S13. PubMed ID: 20532426
[No Abstract] [Full Text] [Related]
28. Therapeutic inertia in the management of dyslipidaemia and hypertension in incident type 2 diabetes and the resulting risk factor burden: Real-world evidence from primary care.
Ling JZJ; Montvida O; Khunti K; Zhang AL; Xue CC; Paul SK
Diabetes Obes Metab; 2021 Jul; 23(7):1518-1531. PubMed ID: 33651456
[TBL] [Abstract][Full Text] [Related]
29. [Management of cardiovascular risk in the elderly patient].
Benoît F
Rev Med Brux; 2014 Sep; 35(4):356-60. PubMed ID: 25675643
[TBL] [Abstract][Full Text] [Related]
30. Type 2 diabetes mellitus: prevention of macrovascular complications.
Meeuwisse-Pasterkamp SH; van der Klauw MM; Wolffenbuttel BH
Expert Rev Cardiovasc Ther; 2008 Mar; 6(3):323-41. PubMed ID: 18327994
[TBL] [Abstract][Full Text] [Related]
31. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
Keech A; Simes RJ; Barter P; Best J; Scott R; Taskinen MR; Forder P; Pillai A; Davis T; Glasziou P; Drury P; Kesäniemi YA; Sullivan D; Hunt D; Colman P; d'Emden M; Whiting M; Ehnholm C; Laakso M;
Lancet; 2005 Nov; 366(9500):1849-61. PubMed ID: 16310551
[TBL] [Abstract][Full Text] [Related]
32. [Cardiovascular protection in diabetic patients with heart disease in the doctor's office].
Eckert S; Tschöpe D
MMW Fortschr Med; 2005 Oct; 147(43):43-6. PubMed ID: 16302422
[TBL] [Abstract][Full Text] [Related]
33. Treatment of the obese patient in primary care: targeting and meeting goals and expectations.
Bray G; Look M; Ryan D
Postgrad Med; 2013 Sep; 125(5):67-77. PubMed ID: 24113665
[TBL] [Abstract][Full Text] [Related]
34. [Therapy of hypertension in patients with type 2 diabetes mellitus].
Hess K
Dtsch Med Wochenschr; 2012 Nov; 137(48):2489-92. PubMed ID: 23114910
[No Abstract] [Full Text] [Related]
35. Lipid-lowering therapy in patients with type 2 diabetes: the case for early intervention.
Steinmetz A
Diabetes Metab Res Rev; 2008; 24(4):286-93. PubMed ID: 18273835
[TBL] [Abstract][Full Text] [Related]
36. Clinical significance of recent lipid trials on reducing risk in patients with type 2 diabetes mellitus.
Jones PH
Am J Cardiol; 2007 Feb; 99(4A):133B-140B. PubMed ID: 17307065
[TBL] [Abstract][Full Text] [Related]
37. Metabolic syndrome: diabetes and cardiovascular disease.
Gupta S; Gupta BM
Indian Heart J; 2006; 58(2):149-52. PubMed ID: 18989060
[TBL] [Abstract][Full Text] [Related]
38. [Lipid-lowering cardiovascular prevention in type 2-diabetes. Statins are effective according to the FIELD study].
Båvenholm P; Attvall S; Nilsson PM
Lakartidningen; 2006 Aug 30-Sep 5; 103(35):2462-6. PubMed ID: 17002161
[No Abstract] [Full Text] [Related]
39. Sugar and fat, a recipe for disaster. New guidelines for the pharmacological management of diabetic dyslipidaemia.
Tallis GA; Beng C; Popplewell P; Phillips P
Aust Fam Physician; 1995 Sep; 24(9):1638-9, 1642-7, 1649. PubMed ID: 7487649
[TBL] [Abstract][Full Text] [Related]
40. The progression of cardiovascular risk to cardiovascular disease.
Rosin BL
Rev Cardiovasc Med; 2007; 8 Suppl 4():S3-8. PubMed ID: 17934392
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
